BrainsWay (BWAY) Q1 2026 earnings review
Operating Leverage Shines, but Cash Flow Lags Earnings
BrainsWay delivered an exceptional first quarter for 2026, with revenue accelerating 35% YoY to $15.5M. The company's strategic pivot toward multi-year enterprise leases and minority investments in mental health clinics is driving intense demand, resulting in a record 117 net Deep TMS shipments (+44% YoY). Operating leverage is fully materializing: Adjusted EBITDA more than doubled to $2.8M as top-line gains easily outpaced controlled operating expenses. Despite strong profitability, operating cash flow dropped steeply YoY due to working capital build-up, leaving a minor blemish on an otherwise stellar quarter.
🐂 Bull Case
The transition to recurring multi-year lease agreements with large enterprise clients provides high visibility. Remaining Performance Obligations (RPO) grew 25% YoY to $75M, insulating the company from macro shocks.
The newly secured insurer coverage for the accelerated SWIFT Deep TMS protocol drastically shortens treatment times, improving unit economics for clinics and heavily incentivizing further system adoption.
🐻 Bear Case
With the previously announced potential 17% reciprocal tariff plan on Israel imports, BrainsWay faces structural margin risks if it cannot pass these costs to U.S. enterprise buyers.
Despite net income doubling to $2.3M, Operating Cash Flow plummeted from $5.0M in 25Q1 to $1.2M in 26Q1, driven by a $3.5M spike in Accounts Receivable and softer deferred revenue growth.
⚖️ Verdict: 🟢
Bullish. The core business is firing on all cylinders with Accelerating growth and expanding margins. While working capital needs monitoring and tariff risks loom, the fundamental shift to a recurring enterprise model is decisively working.
Key Themes
Strategic Clinic Investments Yielding Results
Management's aggressive capital deployment into minority stakes in mental health providers (Stella, Axis, BrainStim) is acting as a powerful captive growth engine. By investing directly into clinics, BrainsWay secures system placements and drives utilization. In 26Q1, the company deployed another $1M to BrainStim Health and $1M to Axis Management, proving this remains a core pillar of their expansion playbook.
Reimbursement Unlocking New Capacity
BrainsWay secured its first insurer coverage for the accelerated SWIFT protocol and expanded U.S. payer support for Psychiatric Mental Health Nurse Practitioners (PMHNPs) to administer TMS. This drastically lowers the bottleneck for clinics, as they no longer need a psychiatrist in the room for every session, structurally improving the ROI of leasing a Deep TMS system.
Neurolief Regulatory Overhang Cleared
In 25Q3, management expressed concern regarding slow FDA administration processes holding up Neurolief's approval. This bottleneck has Reversing momentum: Neurolief achieved FDA Premarket Approval for the ProlivRx system, triggering BrainsWay's $6M milestone-based convertible loan (total investment now $11M) and paving the way for commercialization.
Macro Risk: The 17% Tariff Threat
As noted in prior quarters, the proposed U.S. 17% reciprocal tariff plan on Israel imports represents a severe tail risk. Given that BrainsWay manufactures in Jerusalem and generated over 80% of its H1 2025 revenue in the U.S., any enactment of these tariffs would immediately pressure the company's 75% gross margins unless fully offset by price hikes.
Working Capital Dragging Cash Flow
While profitability looks superb on the income statement, the cash flow statement tells a slightly different story. Operating Cash Flow came in at $1.17M, severely Decelerating from $5.01M a year ago. This was largely due to a $3.45M spike in Trade Receivables (suggesting slower collections) and a normalization of deferred revenue inflows, which previously bolstered cash balances.
Other KPIs
Accelerating. Up 25% YoY and growing sequentially from $65M in 25Q3. This figure firmly validates the multi-year enterprise lease strategy, guaranteeing a highly predictable revenue floor for the upcoming 12-24 months.
Accelerating. Generated $2.8M in Adjusted EBITDA on $15.5M in sales, compared to an 11.2% margin ($1.3M on $11.5M) a year ago. The company is extracting heavy operating leverage from its fixed S&M and R&D bases as volumes scale.
Stable and compounding. The base continues a steady upward march from 1,522 at the end of 25Q2 and 1,600 at the end of 25Q3, fueled by the record 117 net shipments this quarter.
Guidance
Accelerating. Represents a 27% to 30% YoY growth over FY25. This shows confidence that the record Q1 shipment volumes are not a pull-forward, but rather a sustainable new baseline driven by the enterprise lease model.
Accelerating. Implies 86% to 100% growth over FY25. With Q1 already delivering $2.8M, the company is tracking perfectly toward the ~$3.25M quarterly average needed to hit the midpoint, requiring very little heroics in the back half of the year.
Accelerating. Management successfully guided 6-7% for FY25, meaning this metric is expected to double year-over-year. The 26Q1 result of ~12.9% indicates the company is already operating at this target baseline.
Key Questions
Accounts Receivable Build
Trade receivables spiked by $3.45M this quarter, heavily dampening operating cash flow. Is this a symptom of extended payment terms offered to enterprise clients to win bulk lease agreements, or a temporary timing issue?
Tariff Mitigation Strategy
With the potential 17% reciprocal tariff on Israeli imports looming, what concrete steps (e.g., U.S. assembly, forward-purchasing inventory, pricing clauses) has BrainsWay taken to protect the 75% gross margin profile?
Minority Investment Capacity
Cash dropped to $58.9M largely due to $8.5M used for purchasing financial assets (minority stakes). What is the maximum threshold of cash management is willing to deploy into these clinic partnerships before preferring organic reinvestment or share buybacks?